Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Merck Serono Co., Ltd., China | INDUSTRY |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The study will estimate the current status of participants with non-obstructive coronary artery disease confirmed via coronary angiography.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Participants with Coronary Artery Disease | Participants with suspected or confirmed coronary artery disease who underwent coronary angiography during 01 Jan 2013 and 31 Dec 2015 will be observed in the study. |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Percentage of Participants with Non-Obstructive Coronary Artery Disease (CAD) | Up to 10 Months |
| Measure | Description | Time Frame |
|---|---|---|
| Percentage of Participants With Combined Cardiovascular Risk Factors | Combined cardiovascular risk factors include: body mass index, smoking habit, hypertension, hyperlipidemia diabetes mellitus, lack of exercise, alcohol intake and family history of early onset cardiovascular disease. Percentage of participants with combined cardiovascular risk factors will be reported. | Up to 10 Months |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Participants who were suspected or had confirmed coronary artery disease and who underwent coronary angiography between 01 Jan 2013 and 31 Dec 2015 will be observed in the study.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Medical Responsible | Merck Serono Co., Ltd, the biopharmaceutical division of Merck KGaA, Darmstadt, Germany | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Please Contact the Merck KGaA Communication Center | Darmstadt | 64293 | Germany |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Percentage of Participants With Angina Symptoms | Up to 10 months |
| Percentage of Participants With Pathologic Echocardiography Results | Up to 10 Months |
| Ventricular Wall thickness in Participants With Obstructive and Non-Obstructive Coronary Artery Disease (CAD) | Mean left ventricular posterior wall thickness (LVPW), interventricular septum (IVS) thickness, other ventricular wall thickness will be assessed for the participants with obstructive and non-obstructive CAD. | Up to 10 Months |
| Left Ventricular End-Diastolic Volume (LVEDV) in Participants With Obstructive and Non-Obstructive Coronary Artery Disease (CAD) | Up to 10 Months |
| Left Ventricular End Diastolic Diameter (LVEDD) in Participants With Obstructive and Non-Obstructive Coronary Artery Disease (CAD) | Up to 10 Months |
| Ventricular Wall Motion in Participants With Obstructive and Non-Obstructive Coronary Artery Disease (CAD) | Up to 10 Months |
| Ratio of Early Trans-Mitral Flow (E) and Late Trans-Mitral Flow by Atrial Contraction (A) in Participants with Obstructive and Non-Obstructive Coronary Artery Disease (CAD) | Up to 10 Months |
| Left Ventricular Ejection Fraction (LVEF) in Participants with Obstructive and Non-Obstructive Coronary Artery Disease (CAD) | Up to 10 Months |
| Percentage of Participants Receiving Anti-ischemic Drugs | Up to 10 Months |
| Percentage of Participants with Myocardial Event Prevention | Percentage of participants achieving event prevention by antiplatelet agent, anticoagulants, β-blockers, Angiotensin converting enzyme inhibitor (ACEI), Angiotensin receptor blocker (ARB), statin, aldosterone antagonist will be reported. | Up to 10 Months |
| Percentage of Participants With Obstructive and Non-Obstructive Coronary Artery Disease (CAD) Segregated by Age Groups, Genders, Races and Provinces | Up to 10 Months |
| Correlation Coefficient Between Participants With Non-obstructive CAD confirmed by CAG and Clinical Characteristics | Correlation coefficient between the participants with non-obstructive CAD and different clinical characteristics like demographic characteristics, combined cardiovascular risk factors and angina symptoms will be assessed using logistic regression analysis. | Up to 10 Months |